Effectiveness of Organized Mammography Screening for Different Breast Cancer Molecular Subtypes

Ding L, Greuter MJW, Truyen I, Goossens M, Van der Vegt B, De Schutter H, Van Hal G, de Bock GH
Date de publication
Nom du journal
Cancers
Background: Screening program effectiveness is generally evaluated for breast cancer (BC) as one disease and without considering the regularity of participation, while this might have an impact on detection rate.

Objectives: To evaluate the short-term effectiveness of a mammography screening program for the major molecular subtypes of invasive BC.

Methods: All women who participated in the screening program and were diagnosed with screen-detected or interval BC in Flanders were included in the study (2008-2018). Molecular subtypes considered were luminal and luminal-HER2-positive, human epidermal growth factor receptor 2-positive, and triple-negative BC (TNBC). The relationship between the BC stage at diagnosis (early (I-II) versus advanced (III-IV)) and the method of detection (screen-detected or interval) and the relationship between the method of detection and participation regularity (regular versus irregular) were evaluated by multi-variable logistic regression models. All models were performed for each molecular subtype and adjusted for age.

Results: Among the 12,318 included women, BC of luminal and luminal-HER2-positive subtypes accounted for 70.9% and 11.3%, respectively. Screen-detected BC was more likely to be diagnosed at early stages than interval BC with varied effect sizes for luminal, luminal-HER2-positive, and TNBC with OR:2.82 (95% CI: 2.45-3.25), OR:2.39 (95% CI: 1.77-3.24), and OR:2.29 (95% CI: 1.34-4.05), respectively. Regular participation was related to a higher likelihood of screening detection than irregular participation for luminal, luminal-HER2-positive, and TNBC with OR:1.21 (95% CI: 1.09-1.34), OR: 1.79 (95% CI: 1.38-2.33), and OR: 1.62 (95% CI: 1.10-2.41), respectively.

Conclusions: Regular screening as compared to irregular screening is effective for all breast cancers except for the HER2 subtype.